Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 24 — The FDA is seeking comments on the interim results of a study on the workload and costs associated with the review of biosimilar product applications, according to a notice published Sept. 24 in the Federal Register (80 Fed. Reg. 57,621).
The interim report said that as of March 31, the Food and Drug Administration had received a total of 52 investigational new drug applications and pre-investigational new drug applications, participated in 102 biosimilar product development meetings of all types and received five biologics license applications for biosimilar products.
The FDA spent $23.6 million in fiscal year 2013, $21.4 million in FY 2014 and $20.9 million in the first two quarters of FY 2015 for biosimilar-related work, the report said. In total, the FDA has spent $65.9 million over the first 2.5 fiscal years of the program.
The study was conducted by an independent consulting firm, Eastern Research Group of Lexington, Mass., and it fulfills a statutory requirement under the first authorization of the Biosimilar User Fee Act of 2012 (BsUFA), which enables the FDA to collect user fees from companies for the review of biosimilar applications for fiscal years 2013 to 2017, the notice said.
The Affordable Care Act (Pub. L. 111-148) amended the Public Health Service Act to create an abbreviated licensure pathway for biological products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biological product. The agency approved the first, and so far only, biosimilar for the U.S. in March. That biosimilar, Zarxio, is a Sandoz product that is biosimilar to Amgen's cancer drug Neupogen; and Sandoz (part of Novartis) began selling it in September.
BsUFA, part of the FDA Safety and Innovation Act (Pub. L. No. 112-144), authorizes the FDA to assess and collect fees for biosimilar products. The agency uses these fees to expedite the review process for these products.
At a Sept. 17 Senate hearing, an FDA official said there are 57 biosimilars in development and the agency is meeting with the sponsors of those products and has issued three final guidance documents. However, at that hearing, lawmakers criticized the agency for not issuing guidance on topics such as biosimilar labeling and interchangeability.
Comments on the interim report are due Oct. 26 (Docket No. FDA–2015–N–3155).
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The interim report is at http://www.fda.gov/downloads/ForIndustry/UserFees/BiosimilarUserFeeActBsUFA/UCM459686.pdf.
The Federal Register notice is at http://www.gpo.gov/fdsys/pkg/FR-2015-09-24/pdf/2015-24227.pdf.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)